Fierce Pharma

Gilead penned a potential $1.5 billion synthetic lethality deal with [...]

After the pharmaceutical industry spent much of the past year [...]

AstraZeneca has secured a key regulatory win in its effort [...]

After manufacturing the antibiotic Rocephin for four decades—and developing it [...]

Novartis will transfer its 70.68% stake in Novartis India Limited—a [...]

As recent changes to U.S. vaccine policy face pushback on [...]

Throughout 2025, the world’s first metabolic dysfunction-associated steatohepatitis (MASH) drug [...]

In a fourth-quarter conference call, Insmed CEO Will Lewis admitted [...]

An untitled letter shared to the agency’s public database this [...]

With $55 billion earmarked to bolster its U.S. operations, Johnson [...]